https://orcid.org/0000-0002-5341-6857
References
- Xinhua. China Focus: china releases measures to optimize COVID-19 response; 2022. Available from: https://english.news.cn/20221111/d4399114a082438eaac32d08a02bf58d/c.html. Accessed March 22, 2024
- Xinhua. China Focus: COVID-19 response further optimized with 10 new measures; 2022. Available from: https://english.news.cn/20221207/ca014c043bf24728b8dcbc0198565fdf/c.html. Accessed March 22, 2024
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi:10.1056/NEJMoa2118542
- Administration UFaD. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Available from: https://wwwfdagov/media/155050/download. Accessed April 25, 2023.
- World Health Organization. Update to living WHO guideline on drugs for covid-19. BMJ. 2021;374:n2219. doi:10.1136/bmj.n2219
- Health NIo. COVID-19 Treatment Guidelines. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/. Accessed April 26, 2023.
- Wan EYF, Yan VKC, Mok AHY, et al. Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19. Ann Internal Med. 2023;176(4):505–514. doi:10.7326/M22-3057
- Wong CKH, Ich A, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681–1693. doi:10.1016/s1473-3099(22)00507-2
- Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med. 2022;387(9):790–798. doi:10.1056/NEJMoa2204919
- Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023;76(3):e342–e349. doi:10.1093/cid/ciac443
- Ganatra S, Dani SS, Ahmad J, et al. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019. Clin Infect Dis. 2023;76(4):563–572. doi:10.1093/cid/ciac673
- Zheng Q, Ma P, Wang M, et al. Efficacy and safety of Paxlovid for COVID-19: a meta-analysis. J Infect. 2023;86(1):66–117. doi:10.1016/j.jinf.2022.09.027
- A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 (EPIC-HOS). Available from: https://www.clinicaltrials.gov/ct2/show/NCT05545319. Accessed March 14, 2023.
- Chinese Center for Disease Control and Prevention. Nationwide Updates on Novel Coronavirus Infection Situation; 2023. Available from: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202303/t20230311_264174.html. Accessed March 22, 2024.
- Cegolon L, Pol R, Simonetti O, Larese Filon F, Luzzati R. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Pharmaceuticals. 2023;16(5):721. doi:10.3390/ph16050721
- De Vito A, Moi G, Saderi L, et al. Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: a Real-Life Study. Viruses. 2023;15(11):2180. doi:10.3390/v15112180
- Cegolon L, Mastrangelo G, Emanuelli E, Camerotto R, Spinato G, Frezza D. Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: the RENAISSANCE Open-Label Controlled Clinical Trial. Pharmaceutics. 2022;14(11):2502. doi:10.3390/pharmaceutics14112502
- Lin JL, Zhang F, Li YB, et al. Efficacy of physiological seawater nasal irrigation for the treatment of children with SARS-CoV-2 Omicron BA.2 variant infection: a randomized controlled trial. World J Pediatr. 2023. doi:10.1007/s12519-023-00749-z
- McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435–1443. doi:10.1016/s1473-3099(22)00345-0
- Wang Y, Zhao D, Liu X, Chen X, Xiao W, Feng L. Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants. J Med Virol. 2023;95(1):e28443. doi:10.1002/jmv.28443
- Qi T, Jin Y, Wang H, et al. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection. J Med Virol. 2023;95(2):e28497. doi:10.1002/jmv.28497
- Cegolon L, Mauro M, Sansone D, et al. A Multi-Center Study Investigating Long COVID-19 in Healthcare Workers from North-Eastern Italy: prevalence, Risk Factors and the Impact of Pre-Existing Humoral Immunity-ORCHESTRA Project. Vaccines. 2023;11(12). doi:10.3390/vaccines11121769
- Fernández-de-las-Peñas C, Raveendran AV, Giordano R, Arendt-Nielsen L. Long COVID or Post-COVID-19 Condition: past, Present and Future Research Directions. Microorganisms. 2023;11(12):2959. doi:10.3390/microorganisms11122959
- Yip TC, Lui GC, Wong VW, et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut. 2021;70(4):733–742. doi:10.1136/gutjnl-2020-321726
- Wong GL, Hui VW, Yip TC, Lui GC, Hui DS, Wong VW. Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir. Gastroenterology. 2023;164(1):151–153. doi:10.1053/j.gastro.2022.09.008